-$0.89 EPS Expected for Repare Therapeutics Inc. (NASDAQ:RPTX) This Quarter

Equities analysts predict that Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) will post earnings per share of ($0.89) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Repare Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($1.00). Repare Therapeutics reported earnings of ($0.58) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 53.4%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Repare Therapeutics will report full year earnings of ($3.59) per share for the current financial year, with EPS estimates ranging from ($4.25) to ($2.92). For the next fiscal year, analysts forecast that the company will post earnings of ($3.91) per share, with EPS estimates ranging from ($4.21) to ($3.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Repare Therapeutics.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last issued its earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative net margin of 1,406.68% and a negative return on equity of 41.95%. The business had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $3.54 million.

Several research analysts have recently weighed in on the stock. Stifel Nicolaus cut shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Repare Therapeutics in a report on Tuesday, April 12th. The Goldman Sachs Group started coverage on shares of Repare Therapeutics in a report on Thursday, March 17th. They set a “buy” rating and a $43.00 target price for the company. Zacks Investment Research cut shares of Repare Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 5th. Finally, Piper Sandler reduced their target price on shares of Repare Therapeutics from $40.00 to $25.00 in a report on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Shares of RPTX traded down $0.07 during mid-day trading on Friday, hitting $11.68. 142,733 shares of the company traded hands, compared to its average volume of 177,352. The stock has a 50-day moving average price of $13.65 and a two-hundred day moving average price of $18.42. Repare Therapeutics has a 1 year low of $9.59 and a 1 year high of $35.75. The stock has a market cap of $489.11 million, a price-to-earnings ratio of -4.14 and a beta of 0.60.

Large investors have recently modified their holdings of the stock. National Bank of Canada FI bought a new position in shares of Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc raised its stake in Repare Therapeutics by 55.5% during the fourth quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock valued at $83,000 after purchasing an additional 1,400 shares in the last quarter. California State Teachers Retirement System purchased a new stake in Repare Therapeutics during the third quarter valued at $198,000. Virtus ETF Advisers LLC raised its stake in Repare Therapeutics by 28.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after purchasing an additional 1,873 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Repare Therapeutics by 17.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,578 shares of the company’s stock valued at $231,000 after purchasing an additional 1,599 shares in the last quarter. Hedge funds and other institutional investors own 69.41% of the company’s stock.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Further Reading

Get a free copy of the Zacks research report on Repare Therapeutics (RPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.